Market entry autopsy: the reference-pricing withdrawal
A therapy withdrawn from a market that had done nothing wrong.
Cases are anonymised and composited from public events.
In this series we examine how market entry decisions go wrong, so the pattern is easier to see the next time.
What happened
A manufacturer held a well-established therapy, approved and selling across multiple markets, including a small European one where the local price was modest but the market was stable and the patients were real. Nothing about the product had failed. The science held, the approval held, the demand held.
The product was withdrawn from that small market anyway.
The reason had nothing to do with the market it left. Under tightening international reference pricing, that market's low local price had become visible to a much larger, higher-value market, where the manufacturer's revenue dwarfed anything the small market could contribute. Faced with that trade-off, the company protected the large market and exited the small one.
Why it is an autopsy and not just a decision
On the manufacturer's own spreadsheet, this was rational. The revenue at risk in the large market was many multiples of the revenue earned in the small one. But it is worth naming what the decision cost, and what it reveals.
The patients in the small market lost access to a therapy that worked, was approved, and was already on their shelves. The loss was not a failure of science or safety. It was a failure of a system in which the price of a product in one country now determines its availability in another.
For the manufacturer, the episode exposed a gap most companies still have. The withdrawal was reactive. The interdependence between the two markets was discovered late, once the reference-pricing exposure was already on the table, rather than modelled at the point of entry years earlier.
The lesson
The pattern here is not to avoid small markets. It is that the interdependence between markets has to be modelled before entry, not discovered under pressure afterward. When the price you accept in one market can quietly reset the price, or the presence, of your product in another, sequencing and pricing stop being separate decisions.
The manufacturers that will navigate the next several years well are the ones that see this coming at the point of entry, not the point of retreat.